Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.18
-0.90 (-2.43%)
Mar 9, 2026, 1:51 PM EDT - Market open
Cogent Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 63.58 | 43.28 | 34.38 | 26.21 | 19.64 | |
| Research & Development | 269.78 | 232.66 | 173.76 | 121.63 | 55.91 | |
| Operating Expenses | 333.36 | 275.94 | 208.13 | 147.84 | 75.55 | |
| Operating Income | -333.36 | -275.94 | -208.13 | -147.84 | -75.55 | |
| Interest Expense | -3.06 | - | - | - | - | |
| Interest & Investment Income | 14.69 | 18.09 | 13.08 | 3.99 | 0.47 | |
| Other Non Operating Income (Expenses) | -0.02 | 1.99 | 2.64 | 3.61 | 2.81 | |
| EBT Excluding Unusual Items | -321.76 | -255.86 | -192.41 | -140.24 | -72.27 | |
| Other Unusual Items | -7.18 | - | - | - | - | |
| Pretax Income | -328.94 | -255.86 | -192.41 | -140.24 | -72.27 | |
| Earnings From Continuing Operations | -328.94 | -255.86 | -192.41 | -140.24 | -72.27 | |
| Net Income | -328.94 | -255.86 | -192.41 | -140.24 | -72.27 | |
| Net Income to Common | -328.94 | -255.86 | -192.41 | -140.24 | -72.27 | |
| Shares Outstanding (Basic) | 129 | 104 | 80 | 59 | 39 | |
| Shares Outstanding (Diluted) | 129 | 104 | 80 | 59 | 39 | |
| Shares Change (YoY) | 24.09% | 30.48% | 35.41% | 51.89% | 249.52% | |
| EPS (Basic) | -2.55 | -2.46 | -2.42 | -2.38 | -1.87 | |
| EPS (Diluted) | -2.55 | -2.46 | -2.42 | -2.38 | -1.87 | |
| Free Cash Flow | -266 | -208.36 | -156.42 | -125.5 | -60.48 | |
| Free Cash Flow Per Share | -2.06 | -2.00 | -1.96 | -2.13 | -1.56 | |
| EBITDA | -330.8 | -273.49 | -205.86 | -147 | -75.4 | |
| D&A For EBITDA | 2.56 | 2.45 | 2.27 | 0.84 | 0.15 | |
| EBIT | -333.36 | -275.94 | -208.13 | -147.84 | -75.55 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.